

# Resource Summary Report

Generated by [NIF](#) on Sep 20, 2026

## KTCTL-13

RRID:CVCL\_5870

Type: Cell Line

---

### Proper Citation

RRID:CVCL\_5870

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_5870](https://web.expasy.org/cellosaurus/CVCL_5870)

**Proper Citation:** RRID:CVCL\_5870

**Description:** Cell line KTCTL-13 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Clear cell renal cell carcinoma

**Defining Citation:** [PMID:7915601](#), [PMID:8086765](#), [PMID:11929824](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28489074](#), [PMID:30894373](#), [PMID:35839778](#)

**Comments:** Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** KTCTL-13

**Synonyms:** KTCTL13, KTCTL 13, RCC-ER, RCCER

**Cross References:** ArrayExpress:E-MTAB-3610, cancercellines:CVCL\_5870, Cell\_Model\_Passport:SIDM00820, CLS:300238, Cosmic:972923, Cosmic:1352060, Cosmic:1751971, Cosmic-CLP:1524417, DepMap:ACH-002188, EGA:EGAS00001000978, GDSC:1524417, GEO:GSM1670361, Pharmacodb:RCCER\_1288\_2019, PRIDE:PXD030304, Wikidata:Q54900630

**ID:** CVCL\_5870

**Record Creation Time:** 20220427T220710+0000

**Record Last Update:** 20260920T004318+0000

---

## Ratings and Alerts

No rating or validation information has been found for KTCTL-13.

No alerts have been found for KTCTL-13.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Johnson M, et al. (2025) Loss of SETD2 in wild-type VHL clear cell renal cell carcinoma sensitizes cells to STF-62247 and leads to DNA damage, cell cycle arrest, and cell death characteristic of pyroptosis. Molecular oncology, 19(4), 1244.